These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

729 related articles for article (PubMed ID: 33043620)

  • 1. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
    Neuen BL; Arnott C; Perkovic V; Figtree G; de Zeeuw D; Fulcher G; Jun M; Jardine MJ; Zoungas S; Pollock C; Mahaffey KW; Neal B; Heerspink HJL
    Diabetes Obes Metab; 2021 Feb; 23(2):382-390. PubMed ID: 33043620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
    McGuire DK; Shih WJ; Cosentino F; Charbonnel B; Cherney DZI; Dagogo-Jack S; Pratley R; Greenberg M; Wang S; Huyck S; Gantz I; Terra SG; Masiukiewicz U; Cannon CP
    JAMA Cardiol; 2021 Feb; 6(2):148-158. PubMed ID: 33031522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
    Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
    Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.
    Chang R; Liu SY; Zhao LM
    Medicine (Baltimore); 2021 Nov; 100(47):e27802. PubMed ID: 34964748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
    Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
    Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
    ;
    Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study.
    Chang HC; Chen YY; Kuo TT; Lin YJ; Chien KL; Chang HY; Hung CL; Chung FP
    J Am Heart Assoc; 2024 Apr; 13(8):e032397. PubMed ID: 38591334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis.
    Qiu M; Ding L; Zhou H
    Medicine (Baltimore); 2021 Mar; 100(10):e25121. PubMed ID: 33725910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Kunutsor SK; Khunti K; Seidu S
    J R Soc Med; 2024 Aug; 117(8):267-283. PubMed ID: 37734450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
    Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
    JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
    Zhang XL; Zhu QQ; Chen YH; Li XL; Chen F; Huang JA; Xu B
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29353233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
    Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
    Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilization of kidney function and reduction in heart failure events with sodium-glucose co-transporter 2 inhibitors: A meta-analysis and meta-regression analysis.
    Keidai Y; Yoshiji S; Hasebe M; Minamino H; Murakami T; Tanaka D; Fujita Y; Inagaki N
    Diabetes Obes Metab; 2023 Sep; 25(9):2505-2513. PubMed ID: 37217461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
    Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
    Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials.
    Diallo A; Carlos-Bolumbu M; Renard PE; Galtier F
    Diabetes Obes Metab; 2023 Jan; 25(1):166-176. PubMed ID: 36057779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.
    Hinton W; Ansari AS; Whyte MB; McGovern AP; Feher MD; Munro N; de Lusignan S
    Diabetes Obes Metab; 2023 Feb; 25(2):501-515. PubMed ID: 36239122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.